Rare cancers constitute a heterogeneous group of diseases that, although individually with a low incidence, correspond to 20-25% of new cases of malignancies as a group. Despite this fact, rare cancers – including sarcomas – are often overlooked in National Cancer Control Plans (NCCPs), National Non-communicable Chronic Disease Plans (NCDs), and National Rare Diseases Plans (NRDPs). We performed a qualitative review of NCCPs, NCDs, and NRDPs from South American countries, gathered from each ministry of health or equivalent website, and the International Cancer Control Partnership (ICCP) portal. Following an initial assessment of whether rare cancers were mentioned in the documents, we proceeded with an in-depth analysis to provide a descriptive review of how rare cancers and sarcoma were addressed. We reviewed documents from 12 countries within South America – 7 NCCPs, 9 CNDs, 4 NRDPs. Two countries had no documents to be reviewed. Rare cancers are rarely addressed specifically in any of the documents reviewed. For 5/10 countries with documents reviewed, rare cancers were not mentioned specifically in any of the documents analyzed. The document that provided a more in-depth assessment of rare cancers was NCCP from Argentina, which describes a project for telemedicine for rare cancers and, specifically, a pilot project for sarcomas to improve diagnostics, access to multidisciplinary discussion, and appropriate care.Table: 41PCountryDefinitionOrganizationEffective referralHistopathological imagingResearchAccess to orphan drugsPop based databases, registries, biobanksArgentinaXXXXX-XBolivia-------Brazil-X-----Chile-------Colombiax----X-Ecuador-----X-Guyana-------Paraguay-------Peru-X---XXSuriname-------Uruguay-------Venezuela------- Open table in a new tab The limited inclusion of rare cancers in the majority of NCCPs/NCDs/NRDPs from South America suggests a lack of awareness and understanding regarding their unique aspects. It is key to enhance the national policy frameworks that tackle the challenges faced by patients diagnosed with rare cancers – including sarcomas – positioning NCCPs as essential strategic documents in this effort.